المؤلفون: Centers for Disease Control and Prevention, Global Fund

المساهمون: Prof. Gauthier Mesia Kahunu, Professor

المصدر: Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial (TES2022)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06076213Test

المصدر: A Cluster-randomised, Open-label Trial to Compare the Impact of Combined Mass Vaccine and Drug Administrations, Mass Drug Administration, Mass Vaccinations, or no Intervention on Plasmodium Falciparum Malaria Transmission

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06068530Test

المصدر: An Open-label, Randomised, Controlled, Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of a Fixed Dose Triple Artemisinin-based Combination Therapy (TACT) Artemether-lumefantrine-amodiaquine Versus First-line Artemisinin-based Combination Therapies (ACTs) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05951595Test

المؤلفون: MMV, EDCTP, WANECAM

المصدر: A Randomized, Open-label, Multicenter Study to Compare Efficacy, Safety and Tolerability of KLU156 With Coartem® in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Adults and Children ≥ 5 kg Body Weight Followed by an Extension Phase With Repeated KLU156 Treatment

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05842954Test

المؤلفون: The Swedish Research Council, Uppsala University

المساهمون: Billy Ngasala, Associate Professor

المصدر: Holmstrom O, Lder N, Ngasala B, Martensson A, Lder E, Lund M, Moanen H, Suutala A, Dan V, Lund J. Pot-of-care mobe dal mroscopy and deep learng for the detectn of so-transmted helmths and Schtosoma haematobm. Glob Health Actn. 2017 Jun;10(sup3):1337325. do 10.1080/16549716.2017.1337325.
Sm MR, Ochomo EO, AljayyoussG, KwambaTK, Abong'o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gn JE, Samuels AM, DesaMR, Phls-Howard PA, KarkSK, Wang D, Ward SA, Ter Kue FO. Safety and mosquocal effacy of hh-dose ermect when co-admtered wh dydroartem-peraque Kenyan adults wh uncomplated malar (ERMAL): a randomed, double-bld, placebo-controlled trl. Lancet fect D. 2018 Jun;18(6):615-626. do 10.1016/S1473-3099(18)30163-4. Epub 2018 Mar 27.
Dondorp AM, Nosten F, YP, Das D, Phyo AP, Tarng J, Lw KM, Ary F, Hanphakpong W, Lee SJ, Rgwald P, Samut K, wong M, Chotanh K, L P, Herdman T, An SS, Yeung S, Sghasanon P, Day NP, Ldegardh N, Socheat D, Whe NJ. Artem restance Plasmodm falcarum malar. N Engl J Med. 2009 Jul 30;361(5):455-67. do 10.1056/NEJMoa0808859. Erratum : N Engl J Med. 2009 Oct 22;361(17):1714.
Leang R, Taylor WR, Bouth DM, Song L, Tarng J, Char MC, K S, WkowskB, Duru V, Domergue A, Kh N, Rgwald P, Menard D. Evence of Plasmodm falcarum Malar Multrug Restance to Artem and Peraque Western Cambod: Dydroartem-Peraque Open-Label Multenter Clal Assessment. Antrob Agents Chemother. 2015 Aug;59(8):4719-26. do 10.1128/AAC.00835-15. Epub 2015 May 26.
Mwawelo R, Ngasala B, G JP, Malmberg M, Jovel Xu W, PremjZ, Mmbando BP, Bjorkman A, Martensson A. Sustaed Hh Cure Rate of Artemether-Lumefantre agast Uncomplated Plasmodm falcarum Malar after 8 Years of s We-Scale Use Bagamoyo Dtrt, Tanzan. Am J Trop Med Hyg. 2017 Aug;97(2):526-532. do 10.4269/ajtmh.16-0780.
Mwawelo R, Ngasala B, Jovel Xu W, Larsson E, Malmberg M, G JP, PremjZ, Mmbando BP, Martensson A. Prevalence of and Rk Factors Assocted wh Polymerase Cha Reactn-Determed Plasmodm falcarum Posy on Day 3 after tn of Artemether-Lumefantre Treatment for Uncomplated Malar Bagamoyo Dtrt, Tanzan. Am J Trop Med Hyg. 2019 May;100(5):1179-1186. do 10.4269/ajtmh.18-0729.
Can Triple Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria, Delay Drug Resistance Development of Plasmodium Falciparum in Tanzania: a Randomized Three Arm Clinical Trial

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05764746Test

المصدر: A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Patients With Uncomplicated Plasmodium Falciparum Malaria

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05750628Test

المؤلفون: Shin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea, Institute for Advanced Medical Research and Training, University of Ibadan, Ibadan

المساهمون: Adebola E. Orimadegun, Professor

المصدر: Comparative Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in The Treatment of Acute Uncomplicated Malaria Among Children In South-West Nigeria

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05192265Test

المؤلفون: Center for Malariology, Parasitology, and Entomology, Tulane University School of Public Health and Tropical Medicine, University of Massachusetts, Amherst, Centers for Disease Control and Prevention

المصدر: Bousema T, Grf JT, Sauerwe RW, Smh DL, Churcher TS, Takken W, GhanA, Drakeley C, Goslg R. Htg hotspots: spatl targetg of malar for control and elatn. PLoS Med. 2012 Jan;9(1):e1001165. do 10.1371/journal.pmed.1001165. Epub 2012 Jan 31.
Cotter C, Sturrock HJ, Hsng MS, L J, Phls AA, Hwang J, Gueye CS, Fullman N, Goslg RD, Feachem RG. The changg epemlogy of malar elatn: new strategs for new challenges. Lancet. 2013 Sep 7;382(9895):900-11. do 10.1016/S0140-6736(13)60310-4. Epub 2013 Apr 15. Erratum : Lancet. 2013 Sep 7;382(9895):858.
Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smh DL, Abeyasghe RR, Rodruez MH, Maharaj R, Tanner M, Targett G. Operatnal strategs to achve and mata malar elatn. Lancet. 2010 Nov 6;376(9752):1592-603. do 10.1016/S0140-6736(10)61269-X. Epub 2010 Oct 28.
Hustedt J, CanavatSE, Rang C, Ashton RA, Kh N, Berne L, K S, Sovannaroth S, Ly P, Menard D, Cox J, Meek S, Roca-Feltrer A. Reacte case-detectn of malar Pa Provce, Western Cambod: lessons from a year-long evaluatn a pre-elatn settg. Malar J. 2016 Mar 1;15:132. do 10.1186/s12936-016-1191-z.
RossG, Van den Bergh R, Nguon C, Debackere M, Vernaeve L, Kh N, K S, Menard D, De Smet M, Kdermans JM. Adaptg Reacte Case Detectn Strategs for falcarum Malar a Low-Transmsn Area Cambod. Cl fect D. 2018 Jan 6;66(2):296-298. do 10.1093/c/c781.
Das S, Peck RB, Barney R, Jang , Kahn M, Zhu M, Domgo GJ. Performance of an ultra-sense Plasmodm falcarum HRP2-based rap dgnost test wh recombant HRP2, culture parases, and arched whole blood samples. Malar J. 2018 Mar 17;17(1):118. do 10.1186/s12936-018-2268-7. Erratum : Malar J. 2019 Feb 4;18(1):33.
World Health Organatn. (2015). Gueles for the treatment of malar. World Health Organatn
Landr J, Parker DM, Thu AM, Lw KM, Delmas G, Nosten FH; Malar Elatn Task Force Group. Effect of generaled access to early dgnos and treatment and targeted mass drug admtratn on Plasmodm falcarum malar Eastern Myanmar: an observatnal study of a regnal elatn programme. Lancet. 2018 May 12;391(10133):1916-1926. do 10.1016/S0140-6736(18)30792-X. Epub 2018 Apr 24.
Howes RE, DewM, Pl FB, Monteo WM, Battle KE, Messa JP, SakuntabhaA, Satyagraha AW, Wlms TN, Bad JK, Hay S Spatl dtrutn of G6PD defncy varnts across malar-endem regns. Malar J. 2013 Nov 15;12:418. do 10.1186/1475-2875-12-418.
Whe MT, Karl S, Battle KE, Hay S Mueller GhanAC. Modellg the contrutn of the hypnozoe reservo to Plasmodm vax transmsn. Ele. 2014 Nov 18;3:e04692. do 10.7554/eLe.04692.
Douglas NM, Poespoprodjo JR, PatrnD, Malloy MJ, Kenangalem E, Sugrto P, Spson JA, Soenarto Y, Anstey NM, Pre RN. Unsuperved praque for the treatment of Plasmodm vax malar relapses southern Papua: A hospal-based cohort study. PLoS Med. 2017 Aug 29;14(8):e1002379. do 10.1371/journal.pmed.1002379. eCollectn 2017 Aug.
Mtry of Health Lao PDR. The Evaluatn of G6PD Rap Tests and the Use of Praque for the Treatment of Plasmodm Vax fectns Luangprabang, Savannakhet and Champasak Provces (Apr-Nov 2015). (2015)
Center for Malarlogy Parasology and Entomology Lao PDR. Lao PDR Malar Natnal Strateg Plan 2016-2020. (2015).
WHO. Updated WHO poly recommendatn: Sgle dose praque as a gametocytoce Plasmodm falcarum malar. World Health Organatn (2012).
Baum E, Sattabongkot J, Shathop J, Kttutr K, Davs DH, Ja A, Lo E, Lee MC, Randall AZ, Mola DM, Lng X, CuL, Felgner PL, Yan G. Submroscop and asymptomat Plasmodm falcarum and Plasmodm vax fectns are common western Thaand - molecular and serologal evence. Malar J. 2015 Feb 25;14:95. do 10.1186/s12936-015-0611-9.
Corran P, Coleman P, Rey E, Drakeley C. Serology: a robust dator of malar transmsn tensy? Trends Parasol. 2007 Dec;23(12):575-82. do 10.1016/j.pt.2007.08.023. Epub 2007 Nov 7.
Chan CW, Sakama N, Tachana S, r ZM, Lum JK, Tanabe K, Kaneko A. Plasmodm vax and Plasmodm falcarum at the crossroads of exchange among lands Vanuatu: platns for malar elatn strategs. PLoS One. 2015 Mar 20;10(3):e0119475. do 10.1371/journal.pone.0119475. eCollectn 2015.
Beutler E, Duparc S; G6PD Defncy Workg Group. Glucose-6-phosphate dehydrogenase defncy and antalarl drug development. Am J Trop Med Hyg. 2007 Oct;77(4):779-89.
Campbell MK, Pgg G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extensn to cluster randomed trls. BMJ. 2012 Sep 4;345:e5661. do 10.1136/bmj.e5661. No abstract avaable.
Targeting High-risk Populations With Enhanced Reactive Focal Mass Drug Administration: A Study to Assess the Effectiveness and Feasibility for Plasmodium Falciparum and Plasmodium Vivax Malaria in Thailand

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05052502Test

المساهمون: Meta Roestenberg, Principal Investigator

المصدر: Ashley EA, Pyae Phyo A, Woodrow CJ. Malar. Lancet. 2018 Apr 21;391(10130):1608-1621. do 10.1016/S0140-6736(18)30324-6. Epub 2018 Apr 6.
Hoffman SL, Goh LM, Luke TC, Schneer Le TP, Doolan DL, SaccJ, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Rh TL. Protectn of humans agast malar by munatn wh radtn-attenuated Plasmodm falcarum sporozoes. J fect D. 2002 Apr 15;185(8):1155-64. do 10.1086/339409. Epub 2002 Apr 1.
Roestenberg M, McCall M, Hopman J, Wrsma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schak B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Ren L, van der Ven A, Hermsen CC, Sauerwe R. Protectn agast a malar challenge by sporozoe oculatn. N Engl J Med. 2009 Jul 30;361(5):468-77. do 10.1056/NEJMoa0805832.
Safety and Protective Efficacy of Genetically Attenuated Pf∆mei2 (Also Referred to as GA2) Malaria Parasites in Healthy Dutch Volunteers.

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04577066Test

المؤلفون: European and Developing Countries Clinical Trials Partnership (EDCTP)

المصدر: A Phase 2 Interventional, Multicenter, Randomized, Open-label Study in Three Age-descending Cohorts to Evaluate Efficacy, Safety and Tolerability of KAF156 and Lumefantrine-SDF Combination in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in a Pediatric Population

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04546633Test